CW ClaimWatch Consumer alert tracker

Recall

Direct Rx: DULOXETINE D/R, a) 30 mg ( Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Product details: DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

Active Official source

Verification

Official-source record

This page is included in the public index because it is tied to a listed official source. ClaimWatch does not publish trend-only candidates to public SEO pages.

Agency
FDA
Record ID
D-0617-2026
Canonical
https://claimwatch-mvp.vercel.app/item/direct-rx-duloxetine-d-r-a-30-mg/

What happened?

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Product details: DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

Who may be affected?

U.S. Nationwide

What should consumers do?

Affected quantity: 263 Bottles

Official source

Matched search terms

No search trend terms attached yet.

FAQ

Is this page official?

No. ClaimWatch links to official sources and marks whether a page is verified or still being monitored.

Is this legal, medical, or financial advice?

No. This page is informational. Always confirm eligibility, deadlines, and safety instructions through official sources.

Similar alerts